KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) FCF Margin (2018 - 2025)

Historic FCF Margin for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to 9.39%.

  • Castle Biosciences' FCF Margin fell 103800.0% to 9.39% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.39%, marking a year-over-year decrease of 36900.0%. This contributed to the annual value of 11.0% for FY2024, which is 197600.0% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' FCF Margin is 9.39%, which was down 103800.0% from 13.41% recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' FCF Margin peaked at 107.51% during Q4 2021, and registered a low of 170.81% during Q2 2021.
  • Its 5-year average for FCF Margin is 14.09%, with a median of 15.6% in 2023.
  • Its FCF Margin has fluctuated over the past 5 years, first plummeted by -2631800bps in 2021, then soared by 1409400bps in 2022.
  • Castle Biosciences' FCF Margin (Quarter) stood at 107.51% in 2021, then crashed by -119bps to 20.31% in 2022, then soared by 210bps to 22.37% in 2023, then dropped by -13bps to 19.46% in 2024, then crashed by -52bps to 9.39% in 2025.
  • Its FCF Margin stands at 9.39% for Q3 2025, versus 13.41% for Q2 2025 and 12.25% for Q1 2025.